PMID- 20539843
OWN - NLM
STAT- MEDLINE
DCOM- 20100824
LR  - 20211020
IS  - 1178-2048 (Electronic)
IS  - 1176-6344 (Print)
IS  - 1176-6344 (Linking)
VI  - 6
DP  - 2010 Jun 1
TI  - Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart 
      failure.
PG  - 411-8
AB  - For patients presenting with acute dyspnea, an incorrect diagnosis could increase 
      the mortality risk. When used in the evaluation of patients with acute symptoms, 
      brain natriuretic peptide and N-terminal pro-brain natriuretic peptide (BNP and 
      NT-proBNP, respectively) testing is highly sensitive for the diagnosis or 
      exclusion of acute or chronic decompensated heart failure (HF). It has been 
      demonstrated that BNP and proBNP levels can facilitate diagnosis and guide HF 
      therapy. Natriuretic peptide (NP) levels are strictly related with HF severity; 
      they are particularly increased in more advanced New York Heart Association 
      (NYHA) classes and in patients with poor outcome. Therefore elevated NP levels 
      were found to correlate with the severity of left ventricular systolic 
      dysfunction, right ventricular dysfunction and pressures, and left ventricular 
      filling alterations. However, the optimal use of NP determination agrees with 
      patient history, physical examination, and all other diagnostic tools. There are 
      some clinical conditions (ie, obesity, renal insufficiency anemia) for which the 
      NP measurement is not diagnostic. Algorithm building taking into consideration 
      all clinical and echocardiographic parameters, as well as NP measurements, may 
      lead to the earlier identification and better risk stratification of patients 
      with chronic HF, independently from etiology.
FAU - Palazzuoli, A
AU  - Palazzuoli A
AD  - Department of Internal Medicine and Metabolic Diseases, Section of Cardiology Le 
      Scotte Hospital, University of Siena, Italy. palazzuoli2@unisi.it
FAU - Gallotta, M
AU  - Gallotta M
FAU - Quatrini, I
AU  - Quatrini I
FAU - Nuti, R
AU  - Nuti R
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100601
PL  - New Zealand
TA  - Vasc Health Risk Manag
JT  - Vascular health and risk management
JID - 101273479
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Algorithms
MH  - Biomarkers/blood
MH  - Chronic Disease
MH  - Heart Failure/*blood/diagnostic imaging/physiopathology
MH  - Humans
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Assessment
MH  - Severity of Illness Index
MH  - Ultrasonography
MH  - Up-Regulation
MH  - Ventricular Function, Left
MH  - Ventricular Function, Right
PMC - PMC2882893
OTO - NOTNLM
OT  - diagnosis
OT  - echocardiography
OT  - heart failure
OT  - natriuretic pepides
EDAT- 2010/06/12 06:00
MHDA- 2010/08/25 06:00
PMCR- 2010/06/01
CRDT- 2010/06/12 06:00
PHST- 2010/05/25 00:00 [received]
PHST- 2010/06/12 06:00 [entrez]
PHST- 2010/06/12 06:00 [pubmed]
PHST- 2010/08/25 06:00 [medline]
PHST- 2010/06/01 00:00 [pmc-release]
AID - vhrm-6-411 [pii]
AID - 10.2147/vhrm.s5789 [doi]
PST - epublish
SO  - Vasc Health Risk Manag. 2010 Jun 1;6:411-8. doi: 10.2147/vhrm.s5789.